Overview

Scandinavian Cystic Fibrosis Azithromycin Study

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
In patients with Cystic Fibrosis, recurrent airway infection caused by Pseudomonas aeruginosa ultimately leads to chronic airway infection. The purpose of this study is to determine whether supplementary low-dose azithromycin to standard inhaled colistin and oral ciprofloxacin in the treatment of intermittent pseudomonas airway-infection can postpone the next episode of intermittent pseudomonas airway-infection and prevent development of chronic airway-infection.
Phase:
Phase 4
Details
Lead Sponsor:
Rigshospitalet, Denmark
Collaborators:
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation Therapeutics
Treatments:
Azithromycin